Formulation development and in vitro evaluation of didanosine-loaded nanostructured lipid carriers for the potential treatment of AIDS dementia complex

References

• Sweetman SC (2002). Antivirals: Didanosine. In: Sweetman SC, ed. Martindale: the complete drug reference. London: The Pharmaceutical Press, 618–19.
   Google Scholar
• Gibbon CJ (2008). Antivirals for systemic use: Didanosine. In: Gibbon CJ, ed. SAMF: South African Medicines Formulary. Cape Town: Health and Medical Publishing Group, 322.
   Google Scholar
• De Clercq E. (2004). HIV chemotherapy and prophylaxis: New drugs, leads and approaches. Int J Biochem Cell Biol, 36:1800–22.
   PubMed Web of Science ®Google Scholar
• De Clercq E. (2004). Antiviral drugs in current clinical use. J Clin Virol, 30:115–133.
   PubMed Web of Science ®Google Scholar
• Nassar MN, Chen T, Reff MJ, Agharkar SN. (1993). Didanosine. In: Brittain HG, ed. Analytical profiles of drug substances and excipients. New York: Academic Press Inc., 185–227.
   Google Scholar
• Portegies P. (1994). AIDS dementia complex: A review. J Acq Immun Def Synd, 7:S38–S49.
   PubMed Web of Science ®Google Scholar
• Yatvin MB, Li W, Meredith MJ, Shenoy MA. (1999). Improved uptake and retention of lipophilic prodrug to improve treatment of HIV. Adv Drug Deliv Rev, 39:165–82.
   PubMed Web of Science ®Google Scholar
• Portegies P, Enting RH, De Gans J, Algra PR, Derix MMA, Lange JMA, . (1993). Presentation of AIDS dementia complex: 10 years of follow-up in Amsterdam, The Netherlands. AIDS, 7:669–75.
   PubMed Web of Science ®Google Scholar
• McArthurJ.C, Selnes OA, Glass JD, Hoover DR, Bacellar H. (1994). HIV dementia: Incidence and risk factors. In: Price RW, Perry SW, eds. HIV, AIDS and the Brain. New York: Raven Press, 251–72.
   Google Scholar
• Perices M, Cooper DA. (1990). Neuropsychological investigation of patients with AIDS and ARC. J Acq Immun Def Synd, 36:555–64.
   Google Scholar
• Price R, Brew B. (1988). AIDS commentary: The AIDS dementia complex. J Infect Dis, 158:1079–83.
   PubMed Web of Science ®Google Scholar
• Brew BJ. (1999). AIDS dementia complex. Neurol Clin, 17:861–81.
   PubMed Web of Science ®Google Scholar
• Schrager LK, D'Souza MP. (1998). Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. J Am Med Assoc, 280:67–71.
   PubMed Web of Science ®Google Scholar
• Schwarz C, Mehnert W, Lucks JS, Müller RH. (1993). Solid lipid nanoparticles (SLN) for controlled drug delivery I. Production, characterization and sterilization. J Control Release, 30:83–96.
   Web of Science ®Google Scholar
• zur Mühlen A, Schwarz C, Mehnert W. (1998). Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm, 45:149–55.
   PubMed Web of Science ®Google Scholar
• Müller RH, Mäder K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm, 50:161–77.
   PubMed Web of Science ®Google Scholar
• Müller RH, Mehnert W, Lucks JS, Schwarz C, zur Mühlen A, Wyhers H, . (1995). Solid lipid nanoparticles (SLN): An alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm, 41:62–69.
   Web of Science ®Google Scholar
• Mehnert W, Mäder K. (2001). Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev, 47:165–96.
   PubMed Web of Science ®Google Scholar
• Müller RH, Radtke M, Wissing SA. (2002). Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm, 242:121–28.
   PubMed Web of Science ®Google Scholar
• Radtke M, Souto EB, Müller RH. (2005). Nanostructured lipid carriers: A novel generation of solid lipid drug carriers. Pharm Tech Eur, 17:45–50.
   Google Scholar
• Radtke M, Müller RH. (2001). Nanostructured lipid carriers. New Drugs, 2:48–52.
   Google Scholar
• Müller RH, Radtke M, Wissing SA. (2002). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev, 54:S131–55.
   PubMed Web of Science ®Google Scholar
• Wissing SA, Kayser O, Müller RH. (2004). Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev, 58:1257–72.
   Google Scholar
• Pal Kaur I, Bhandari R, Bhandari S, Kakkar V. (2007). Potential of solid lipid nanoparticles in brain targeting. J Control Release, 127:97–109.
   Web of Science ®Google Scholar
• Müller RH, Keck CM. (2004). Drug delivery to the brain-realization by novel drug carriers. J Nanosci Nanotechnol, 4:471–83.
   PubMed Web of Science ®Google Scholar
• Göppert TM, Müller RH. (2005). Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: Comparison of plasma protein adsorption patterns. J Drug Target, 13:179–87.
   PubMed Web of Science ®Google Scholar
• Souto EB, Anselmi C, Centini M, Müller RH. (2005). Preparation and characterization of n-dodecyl-ferulate-loaded solid lipid nanoparticles (SLN®). Int J Pharm, 295:261–68.
   PubMed Web of Science ®Google Scholar
• Teeranachaideekul V, Souto EB, Müller RH, Junyaprasert V. (2008). Physicochemical characterization and in vitro release studies of ascorbyl palmitate-loaded semi-solid nanostructured lipid carriers (NLC gels). J Microencapsulation, 25:111–20.
   PubMed Web of Science ®Google Scholar
• Souto EB, Müller RH. (2005). SLN and NLC for topical delivery of ketoconazole. J Microencapsulation, 22:501–10.
   PubMed Web of Science ®Google Scholar
• Lim SJ, Kim CK. (2002). Formulation parameters determining the physicochemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid. Int J Pharm, 243:135–46.
   PubMed Web of Science ®Google Scholar
• Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP. (2003). Physicochemical stability of colloidal lipid particles. Biomaterials, 24:4283–300.
   PubMed Web of Science ®Google Scholar
• Radomska-Soukharev A. (2007). Stability of lipid excipients in solid lipid nanoparticles. Adv Drug Deliv Rev, 59:411–18.
   PubMed Web of Science ®Google Scholar
• Joshi M, Patravale V. (2007). Nanostructured lipid carrier (NLC) based gel of celecoxib. Int J Pharm, 346:124–32.
   PubMedGoogle Scholar
• Teeranachaideekul V, Souto EB, Junyaprasert VB, Müller RH. (2007). Cetyl palmitate-based NLC for topical delivery of Coenzyme Q10 – Development, physicochemical characterization and in vitro release studies. Eur J Pharm Biopharm, 67:141–48.
   PubMed Web of Science ®Google Scholar
• Westesen K, Siekmann B, Koch MHJ. (1993). Investigations on the physical state of solid lipid nanoparticles by synchrom radiation X-ray diffraction. Int J Pharm, 93:189–99.
   Web of Science ®Google Scholar
• Dingler A, Blum RP, Niehus H, Müller RH, Gohla S. (1999). Solid lipid nanoparticles (SLN/Lipopearls): A pharmaceutical and cosmetic carrier for the application of vitamin E in dermal products. J Microencapsulation, 16:751–67.
   PubMed Web of Science ®Google Scholar
• Souto EB, Müller RH. (2006). Investigation of the factors influencing the incorporation of clotrimazole in SLN and NLC prepared by hot high-pressure homogenization. J Microencapsulation, 23:377–88.
   PubMed Web of Science ®Google Scholar
• Schubert MA, Müller-Goymann CC. (2005). Characterization of surface-modified solid lipid nanoparticles (SLN): Influence of lecithin and non-ionic emulsifier. Eur J Pharm Biopharm, 61:77–86.
   PubMed Web of Science ®Google Scholar
• Saupe A, Wissing SA, Lenk A, Schmidt C, Müller RH. (2005). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)-structural investigations on two different carrier systems. Biomed Mater Eng, 15:393–402.
   PubMed Web of Science ®Google Scholar
• Luo Y, Chen D, Ren L, Zhao X, Qin J. (2006). Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J Control Release, 114:53–59.
   PubMed Web of Science ®Google Scholar
• Ugazio E, Cavalli R, Gasco MR. (2002). Incorporation of cyclosporin A in solid lipid nanoparticles (SLN). Int J Pharm, 241:341–44.
   PubMed Web of Science ®Google Scholar
• Liu J, Hu W, Chen H, Ni Q, Xu H, Yang X. (2007). Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int J Pharm, 328:191–95.
   PubMed Web of Science ®Google Scholar
• Wissing SA, Müller RH, Manthei L, Meyer C. (2004). Structural characterization of Q10-loaded solid lipid nanoparticles by NMR spectroscopy. Pharm Research, 21:400–05.
   PubMed Web of Science ®Google Scholar
• Müller RH, Runge SA, Ravelli V, Thünemann AF, Mehnert W, Souto EB. (2008). Cyclosporine-loaded solid lipid nanoparticles (SLN®): Drug-lipid physicochemical interactions and characterization of drug incorporation. Eur J Pharm Biopharm, 68:535–44.
   PubMed Web of Science ®Google Scholar
• Saunders M, Podluii K, Shergill S, Buckton G, Royall P. (2004). The potential of high speed DSC (Hyper-DSC) for the detection and quantification of small amounts of amorphous content in predominantly crystalline samples. Int J Pharm, 274:35–40.
   PubMed Web of Science ®Google Scholar
• Saklatvala R, Royall PG, Craig DQM. (1999). The detection of amorphous material in a nominally crystalline drug using modulated temperature DSC – A case study. Int J Pharm, 192:55–62.
   PubMed Web of Science ®Google Scholar
• PANanlytical application notes. (2010). Crystallinity determination: quantification of low amounts of amorphous material in a crystalline matrix and vice versa. The Netherlands: PANanalytical B.V. http://www.xrdml.com/index.cfm?pid=224&itemID= 162&contentItemID =114 [accessed April 8, 2010].
   Google Scholar
• Hernqvist L. (1988). Crystal structures of fats and fatty acids. In: Garti N, Sato K, eds. Crystallization and polymorphism of fats and fatty acids. New York: Marcel Dekker Inc., 97–137.
   Google Scholar